Flarin’s Philip Lindsell: UK ITV Backing Could Provide Springboard For International Expansion

Flarin Holdings recently secured £5m ($6.2m) investment from UK television company ITV's Media for Equity fund in return for a minority stake in the company, which markets analgesic brand Flarin in the UK. The investment could be a springboard for international expansion, including in the US, Flarin's managing director Philip Lindsell tells HBW Insight in an exclusive in-depth interview.

International business concept with businessman and digital map superimposed on a city skyline background.
• Source: Shutterstock

Backing from a UK television company's investment vehicle will provide a springboard for the international expansion of fast-growing analgesic Flarin, hopes Flarin Holdings Ltd's managing director Philip Lindsell.

More from United Kingdom

Kenvue Survey Shows UK Pharmacists United Behind Self-Care Solutions

 
• By 

A recent Kenvue survey shows that an overwhelming majority of UK pharmacists believe many health issues could be prevented through better self-care.

First UK CBD Novel Food Authorizations Expected In 2025

 
• By 

FSA now aims to send the first recommendations for the authorization of CBD novel food products to UK government ministers in 2025, according to its most recent board meeting. The agency is closely scrutinizing trace THC levels and is planning to ban use of CBD food products by under 18s.

OTC Marketing Awards 2024: What The Judges Said About The Leading Entries

 
• By 

The trophies have been presented at the OTC Marketing Awards 2024 - but what did the judging panel have to say about the winning and highly-commended entries?

Opella Crowned Company Of The Year At OTC Marketing Awards 2024

 
• By 

Winners across 12 categories were announced at the OTC Marketing Awards 2024 on 21 November, with Opella taking the top prize as OTC Company of the Year.

More from Europe

Bayer Drops Plan For EU OTC Antifungal Launch After Poor Trial Results

 
• By 

Bayer Consumer Health shelves European launch of topical OTC onychomycosis treatment under its Canesten brand after a Phase III trial of the product - developed by Sweden's Moberg Pharma - failed to meet its primary endpoint.

EU Urban Wastewater Directive ‘Highly Disproportionate,’ Says AESGP

 
• By 

Pharmaceutical industry associations are united in their view that the revised EU Urban Wastewater Treatment Directive discriminates against medicines and cosmetics producers.

France's Unither Acquires Virus-Blocking Nasal Spray From Marinomed

 
• By 

French CDMO Unither has snapped up Marinomed's Carragelose virus-blocking compound, which is used in OTC nasal sprays marketed by leading consumer health players such as Perrigo and Reckitt.